ANI Pharmaceuticals Financials - Benzinga

ANI Pharmaceuticals Inc

ANIPNASDAQ

Trade with Public

Trade with Public

$73.51

-1.05-1.41%

At close: Aug 27, 5:00 PM EST

$73.51

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

ANI Pharmaceuticals Financials

ANI Pharmaceuticals (ANIP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.

Avi Kapoor

PRO
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est

ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140

Benzinga Newsdesk

PRO
ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 by 7.8 percent. This is a 22.78 percent increase over earnings of $1.80 per share from

Benzinga Newsdesk

PRO
ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 Est; Raises FY2026 Sales Guidance from $1.055B-$1.115B to $1.080B-$1.140B vs $1.050B Est.

ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 analyst estimate. Raises FY2026 sales outlook from $1.055 billion-$1.115 billion to $1.080 billion-$1.140 billion

Benzinga Newsdesk

PRO
ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate.

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.30 by 56.49 percent. This is a 20.59 percent increase over earnings of $1.70 per share from

Benzinga Newsdesk

ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%

ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Disease revenue surges 50%.

Vandana Singh